2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Recurrent Adult T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
38 Active assets in the Recurrent Adult T-Cell Leukemia/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide John Reneau | Phase 4 | BBB |
DEXAMETHASONE The First Affiliated Hospital of Soochow University | Phase 2 | BBB |
Fludarabine John Reneau | Phase 2 | BBB |
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BBB |
cc-5013 National Cancer Institute (NCI) | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →